Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 201–300 of 963
Melin, E. O., Thulesius, H. O., Hillman, M., Svensson, R., Landin‐Olsson, M., & Thunander, M. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1009-4 · Cited by 38
“Data were collected from electronic health records and the Swedish National Diabetes Register (S-NDR) [16].”
BackgroundMethodInfluentialTougaard, N. H., Frimodt‐Møller, M., Salmenkari, H., STOUGAARD, E. B., de Zawadzki, A., Mattila, I. M., Hansen, T. W., Legido‐Quigley, C., Hörkkö, S., Forsblom, C. M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133573 · Cited by 36
Hering, B. J., & O’Connell, P. J. (2016) · Xenotransplantation · doi:10.1111/xen.12228 · Cited by 37
Growth in patients with type 1 diabetes
Mitchell, D. M. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000310 · Cited by 42
Benhamou, P., Adenis, A., Lebbad, H., Tourki, Y., Heredia, M., Gehr, B., Franc, S., & Charpentier, G. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15008 · Cited by 35
Bone Microarchitecture in Type 1 Diabetes: It Is Complicated
Keenan, H. A., & Maddaloni, E. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0338-8 · Cited by 34
Melin, E. O., Thulesius, H. O., Hillman, M., Landin‐Olsson, M., & Thunander, M. (2018) · BMC Obesity · doi:10.1186/s40608-018-0193-5 · Cited by 43
Piona, C., Dovc, K., Mutlu, G. Y., Grad, K., Gregorc, P., Battelino, T., & Bratina, N. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12729 · Cited by 34
Wang, Z., Bao, Z., Ding, Y., Xu, S., Du, R., Yan, J., Li, L., Sun, Z., Shao, C., & Gu, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108880 · Cited by 34
González‐Pérez, A., Sáez, M. E., Vizcaya, D., Lind, M., & Rodríguez, L. A. G. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.11.002 · Cited by 39
Self-citationClinical characteristics and management of type 1 diabetes in Spain. The SED1 study
Peralta, F. G., Torre, E. L. M., Conde, S., Conget, I., & Novials, A. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.11.020 · Cited by 51
Kobayati, A., Haidar, A., & Tsoukas, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14637 · Cited by 39
PAULEY, M. E., Tommerdahl, K. L., Snell‐Bergeon, J. K., & Forlenza, G. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01799-x · Cited by 46
Semova, I., Levenson, A. E., Krawczyk, J., Bullock, K., Williams, K. A., Wadwa, R. P., Shah, A. S., Khoury, P. R., Kimball, T. R., Urbina, E. M., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.09.008 · Cited by 33
Low carbohydrate high fat ketogenic diets on the exercise crossover point and glucose homeostasis
Noakes, T. D., Prins, P. J., Volek, J. S., D’Agostino, D. P., & Koutnik, A. P. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1150265 · Cited by 33
“While the exact consequences of these prediabetic glucose values in populations regularly engaging in physical activity requires additional analyses, and additional confirmation is warranted, it appears unlikely that persistent and elevated glucose values would be recommended granted the demonstrated adverse effects o…”
BackgroundAutomated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1c
Boucsein, A., Zhou, Y., Michaels, V. R., Haszard, J. J., Jefferies, C., Wiltshire, E. J., Paul, R. G., Parry‐Strong, A., Pasha, M., Petrovski, G., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400185 · Cited by 38
Explaining the increased mortality in type 1 diabetes
Mameli, C., Mazzantini, S., Nasr, M. B., Fiorina, P., Scaramuzza, A. E., & Zuccotti, G. V. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i7.889 · Cited by 42
A new model to estimate insulin resistance via clinical parameters in adults with type 1 diabetes
Zheng, X., Huang, B., Luo, S., Yang, D., Bao, W., Li, J., Yao, B., Weng, J., & Yan, J. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2880 · Cited by 35
Viñals, C., Conget, I., Pané, A., Boswell, L., Perea, V., Blanco, J., Ruiz, S., Giménez, M., Vinagre, I., Esmatjes, E., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3320 · Cited by 35
“The risk of CVD in people with T1D is higher than for those without diabetes, even in individuals with good metabolic control.(1,2) A recent study”
BackgroundLDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes
Hero, C., Svensson, A., Gidlund, P., Guðbjörnsdóttir, S., Eliasson, B., & Eeg‐Olofsson, K. (2015) · Diabetic Medicine · doi:10.1111/dme.13007 · Cited by 39
Self-citationSpark, T. L., Maahs, D. M., Bishop, F. K., Snell‐Bergeon, J. K., & Wadwa, R. P. (2016) · International Journal of Pediatric Endocrinology · doi:10.1186/s13633-016-0026-6 · Cited by 36
Influence of HbA1c and BMI on Lipid Trajectories in Youths and Young Adults With Type 1 Diabetes
Katz, M. L., Kollman, C., Dougher, C. E., Mubasher, M., & Laffel, L. M. (2016) · Diabetes Care · doi:10.2337/dc16-0430 · Cited by 32
Marfil‐Garza, B. A., Hefler, J., Verhoeff, K. K., Lam, A. P., Dajani, K. Z., Anderson, B. L., O’Gorman, D., Kin, T., Bello‐Chavolla, O. Y., Grynoch, D., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005783 · Cited by 38
Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study
Vélayoudom‐Céphise, F., Rajaobelina, K., Helmer, C., Nov, S., Pupier, É., Blanco, L., Hugo, M., Farges, B., Astrugue, C., Gin, H., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0448-8 · Cited by 34
Wang, G., Ma, K., Zhang, Y., Hu, Z., Liu, L., Lü, J., Chen, P., Lü, C., Ruan, X. Z., & Liu, B. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0186-4 · Cited by 32
Sterner Isaksson, S., Bensow Bacos, M., Eliasson, B., Thors Adolfsson, E., Rawshani, A., Lindblad, U., Jendle, J., Berglund, A., Lind, M., & Axelsen, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001971 · Cited by 31
Self-citationDepression in type 1 diabetes was associated with high levels of circulating galectin-3
Melin, E. O., Dereke, J., Thunander, M., & Hillman, M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0108 · Cited by 31
Ajjan, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16098 · Cited by 40
Individualized Glycemic Goals and an Expanded Classification of Severe Hypoglycemia in Diabetes
Cryer, P. E. (2017) · Diabetes Care · doi:10.2337/dc16-1741 · Cited by 31
Basu, A., Alman, A. C., & Snell‐Bergeon, J. K. (2019) · Nutrition Journal · doi:10.1186/s12937-019-0449-z · Cited by 36
“Poor glycemic control in T1D has been associated with excess mortality and cardiovascular disease (CVD) when compared to non-diabetic matched controls [20, 21], and few adults with T1D meet current glycemic control targets [20], thus necessitating additional preventive strategies such as dietary fiber intake in this h…”
BackgroundClinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease
Karalliedde, J. J., Winocour, P. H., Chowdhury, T. A., De, P., Frankel, A., Montero, R., Pokrajac, A., Banerjee, D., Dasgupta, I., Fogarty, D. G., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14769 · Cited by 43
Katz, M. L., Giani, E., & Laffel, L. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0692-4 · Cited by 38
Chantzichristos, D., Persson, A., Eliasson, B., Miftaraj, M., Franzén, S., Bergthorsdottir, R., Gudbjörnsdottir, S., Svensson, A.-M., & Johannsson, G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0657 · Cited by 30
Self-citationFeingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 51
Metabolic Karma—The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture
Cooper, M. E., El‐Osta, A., Allen, T. J., Watson, A. M. D., Thomas, M. C., & Jandeleit-Dahm, K. A. M. (2018) · Diabetes · doi:10.2337/dbi18-0010 · Cited by 33
Pettus, J., Zhou, F. L., Shepherd, L. C., Mercaldi, K., Preblick, R., Hunt, P. R., Paranjape, S., Miller, K. M., & Edelman, S. V. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13937 · Cited by 36
“CV disease remains the number one cause of mortality in T1D, but the risk is not completely explained by hyperglycaemia.(19) Patients with T1D with ideal glycaemic control (HbA1c <7% [53 mmol/mol]) still have an approximately twofold increased risk of CV disease compared with people without diabetes.”
BackgroundCombating atherosclerosis with targeted Diosmin nanoparticles-treated experimental diabetes
Hendawy, O. M., El‐Naggar, M. E., El-Banna, M., Fouda, M. M. G., Othman, S. I., Allam, A. A., & Morsy, O. M. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00905-6 · Cited by 33
“Diabetes mellitus (DM) is a vastly prevalence metabolic disorder associated by higher blood sugar level over prolonged duration causing intimal blood vessel damage and predisposing atherosclerotic disease [2].”
BackgroundTecce, N., Masulli, M., Lupoli, R., Pepa, G. D., Bozzetto, L., Palmisano, L., Rivellese, A. A., Riccardi, G., & Capaldo, B. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01137-x · Cited by 36
The Imbalance of Mitochondrial Fusion/Fission Drives High-Glucose-Induced Vascular Injury
Zheng, Y., Luo, A., & Liu, X. (2021) · Biomolecules · doi:10.3390/biom11121779 · Cited by 34
Bebu, I., Braffett, B. H., Schade, D., Sivitz, W., Malone, J. I., Pop-Busui, R., Lorenzi, G. M., Lee, P., Trapani, V. R., Wallia, A., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0226 · Cited by 29
Cariou, B., Leiter, L. A., Müller‐Wieland, D., Bigot, G., Colhoun, H. M., Prato, S. D., Henry, R. R., Tinahones, F. J., Letierce, A., Aurand, L. A., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.01.004 · Cited by 29
Islet-Derived eATP Fuels Autoreactive CD8+ T Cells and Facilitates the Onset of Type 1 Diabetes
Tezza, S., Nasr, M. B., D’Addio, F., Vergani, A., Usuelli, V., Falzoni, S., Bassi, R., Dellepiane, S., Fotino, C., Rossi, C., et al. (2018) · Diabetes · doi:10.2337/db17-1227 · Cited by 30
“despite much effort, an immune-based cure for T1D does not exist, and concern remains due to the increased risk of mortality associated with the disorder (6).”
BackgroundSeidu, S., Barratt, J., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.02.006 · Cited by 33
The Role of Epigenetic Modifications in Late Complications in Type 1 Diabetes
Kern, B. Č., Podkrajšek, K. T., Kovač, J., Šket, R., Bizjan, B. J., Tesovnik, T., Debeljak, M., Battelino, T., & Bratina, N. (2022) · Genes · doi:10.3390/genes13040705 · Cited by 40
Diabetic Kidney Disease: Is There a Role for Glycemic Variability?
Subramanian, S., & Hirsch, I. B. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0979-3 · Cited by 35
Navodnik, M. P., Janež, A., & Žuran, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071945 · Cited by 28
“Hyperglycemia appears to have a more profound effect on cardiovascular risk in T1DM, while, in T2DM, achievement of treatment targets for all recognized risk factors is crucial [7,8].”
BackgroundSamuelsson, J., Bertilsson, R., Bülow, E., Carlsson, S., Åkesson, S., Eliasson, B., Hanås, R., & Åkesson, K. (2024) · Diabetologia · doi:10.1007/s00125-024-06086-8 · Cited by 37
Mohammedi, K., Potier, L., Belhatem, N., Matallah, N., Hadjadj, S., Roussel, R., Marre, M., & Velho, G. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0322-0 · Cited by 29
Identifying Causes for Excess Mortality in Patients With Diabetes: Closer but Not There Yet
Yu, O. H. Y., & Suissa, S. (2016) · Diabetes Care · doi:10.2337/dci16-0026 · Cited by 31
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 36
Tönnies, T., Stahl‐Pehe, A., Bächle, C., Castillo, K., Kuß, O., Yossa, R., Lindner, L. M. E., Holl, R. W., & Rosenbauer, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/7806980 · Cited by 31
Llauradó, G., Amigó, N., Cano, A., Ballesta, S., Albert, L., Mazarico, I., Fernández‐Veledo, S., Pedro‐Botet, J., Vendrell, J. J., & González-Clemente, J. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111875 · Cited by 29
Luo, D., Gu, W., Bao, Y., Cai, X., Lu, Y., Li, R., Wang, Y., & Li, M. (2021) · Journal of Clinical Nursing · doi:10.1111/jocn.15739 · Cited by 35
Fructose Metabolism and Cardiac Metabolic Stress
Annandale, M., Daniels, L. J., Li, X., Neale, J. P. H., Chau, A. H. L., Ambalawanar, H. A., James, S. L., Koutsifeli, P., Delbridge, L. M. D., & Mellor, K. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695486 · Cited by 31
Andelin, M., Kropff, J., Matuleviciene, V., Joseph, J. I., Attvall, S., Theodorsson, E., Hirsch, I. B., Imberg, H., Dahlqvist, S., Klonoff, D., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815626724 · Cited by 28
Self-citationHanes, W. M., Olofsson, P. S., Kwan, K., Hudson, L., Chavan, S. S., Pavlov, V. A., & Tracey, K. J. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00142 · Cited by 29
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 44
Lou, Y., Kong, M., Li, L., Hu, Y., Zhai, W., Qi, X., Liu, Z., & Wu, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/7866720 · Cited by 35
Jacobsen, L. M., & Schatz, D. (2026) · JAMA · doi:10.1001/jama.2026.0048 · Cited by 34
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Pehrsson, N.-G., & Moström, P. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816642578 · Cited by 27
Self-citationIslet Cell Transplantion: Update on Current Clinical Trials
Schuetz, C., & Markmann, J. F. (2016) · Current Transplantation Reports · doi:10.1007/s40472-016-0103-z · Cited by 34
Wang, T. K. M., Woodhead, A., Ramanathan, T., & Pemberton, J. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.05.117 · Cited by 32
“one study found [40_TD$DIFF]type [2_TD$DIFF]1 [41_TD$DIFF]diabetics [42_TD$DIFF]with [43_TD$DIFF]HbA1 [44_TD$DIFF]c<7%had double the mortality of matched controls, meaning that excessive lowering of HbA1c may be harmful [16].”
ResultAhmed, M. O., Byrne, R., Pazderska, A., Segurado, R., Guo, W., Gunness, A., Frizelle, I. M., Sherlock, M., Ahmed, K. S., McGowan, A. N., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05320-3 · Cited by 28
“Despite many improvements in the management of type 1 diabetes, life expectancy for affected individuals remains approximately 12 years less than for the non-diabetic population [1, 2].”
BackgroundSchweiger, D. Š., Battelino, T., & Grošelj, U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910192 · Cited by 31
Mesa, A., Giménez, M., Pueyo, I., Perea, V., Viñals, C., Blanco, J., Vinagre, I., Serés‐Noriega, T., Boswell, L., Esmatjes, E., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109938 · Cited by 30
Ståhl, C. H., Lind, M., Svensson, A. ‐., Guðbjörnsdóttir, S., Mårtensson, A., & Rosengren, A. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12572 · Cited by 31
Self-citationRacial and Ethnic Disparities in the Burden and Cost of Diabetes for US Medicare Beneficiaries
GLANTZ, N. M., Duncan, I. G., Ahmed, T., Fan, L., Reed, B. L., Kalirai, S., & Kerr, D. E. (2019) · Health Equity · doi:10.1089/heq.2019.0004 · Cited by 31
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Volčanšek, Š., Koceva, A., Jensterle, M., Janež, A., & Muzurović, E. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01733-8 · Cited by 35
Therapies to Preserve β-Cell Function in Type 1 Diabetes
Ludvigsson, J. (2015) · Drugs · doi:10.1007/s40265-015-0511-x · Cited by 30
Brunström, M., Eliasson, M., Nilsson, P. M., & Carlberg, B. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001183 · Cited by 27
Goltsman, D., Morrison, K. A., & Ascherman, J. A. (2017) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000001461 · Cited by 31
Petersen, K. S., Keogh, J. B., Lister, N. B., & Clifton, P. M. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.05.001 · Cited by 29
Samuelsson, J., Samuelsson, U., Hanberger, L., Bladh, M. K., & Åkesson, K. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12980 · Cited by 35
“As has been shown by Rawshani et al, age at diagnosis is an important risk factor for premature death, most emphasized in cardiovascular cause of death, raising the question whether cardioprotective medication should be considered earlier than in current practice.29 Our results compliment the picture as data regarding…”
BackgroundResultInfluentialPersonalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?
Deligne, C., You, S., & Mallone, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040542 · Cited by 27
Hallström, S., Wijkman, M. O., Ludvigsson, J., Ekman, P., Pfeffer, M. A., Wedel, H., Rosengren, A., & Lind, M. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100469 · Cited by 40
Self-citationGianini, A., Suklan, J., Skela‐Savič, B., Klemenčič, S., Battelino, T., Dovč, K., & Bratina, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.967725 · Cited by 27
“The principal goal in the management of T1DM is to maintain blood glucose levels as close to normal as possible with the aim of avoiding or delaying diseaserelated micro and macrovascular complications, which represent the major cause of morbidity and mortality in developed societies (2, 3).”
BackgroundPinckney, A., Rigby, M. R., Keyes-Elstein, L., Soppe, C. L., Nepom, G. T., & Ehlers, M. R. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.032 · Cited by 28
Petersen, K. S., Smith, J. M., Clifton, P. M., & Keogh, J. B. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515003748 · Cited by 27
The Potential of Learning Health Care Systems
Maddox, T. M., & Ferguson, T. B. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.050 · Cited by 26
Boggi, U., Baronti, W., Amorese, G., Pilotti, S., Occhipinti, M., Perrone, V., Marselli, L., Barsotti, M., Campani, D., Gianetti, E., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000003627 · Cited by 25
Suicide and Self-inflicted Injury in Diabetes: A Balancing Act
Barnard-Kelly, K. D., Naranjo, D. M., Majidi, S., Aktürk, H. K., Breton, M. D., Courtet, P., Olié, É., Lal, R., Johnson, N., & Renard, É. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819891136 · Cited by 30
“While new technologies have proven benefits in avoiding diabetes-related complications(17) and may have reduced excess mortality in some populations,(18) both mortality and complication rates remain significantly higher in T1DM when compared to the general population.(19,20) Furthermore, the additional workload associ…”
BackgroundChen, X., Zhou, P., Zhang, M., Xu, Z., Zhao, Z., Lü, W., Chen, L., Luo, F., Chen, T., & Sun, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.651589 · Cited by 35
“Recent population-based studies in adults confirmed that higher HbA1c concentration is associated with increased diabetic complications (10) and complication-related mortality (11).”
BackgroundRaman, S., Dai, H. D., DeLurgio, S. A., Williams, D. D., Lind, M., Patton, S. R., Spertus, J. A., Kosiborod, M., & Clements, M. A. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12300 · Cited by 27
Self-citationImmune interventions to preserve β cell function in type 1 diabetes
Ehlers, M. R. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000227 · Cited by 31
Cardiovascular complications of type 1 diabetes: update on the renal link
Orchard, T. J., & Costacou, T. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0949-7 · Cited by 29
Islet Transplantation Alone Versus Solitary Pancreas Transplantation: an Outcome-Driven Choice?
Maffi, P., & Secchi, A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1145-2 · Cited by 27
Fabris, C., Nass, R. M., Pinnata, J., Carr, K., Koravi, C. L. K., Barnett, C. L., Oliveri, M. C., Anderson, S. M., Cherñavvsky, D. R., & Breton, M. D. (2020) · Diabetes Care · doi:10.2337/dc19-1675 · Cited by 25
Samuelsson, U., Anderzén, J., Åkesson, K., & Hanberger, L. (2020) · Acta Paediatrica · doi:10.1111/apa.15591 · Cited by 29
β-cell replacement sources for type 1 diabetes: a focus on pancreatic ductal cells
Corritore, E., Lee, Y.-S., Sokal, E. M., & Lysy, P. A. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816652059 · Cited by 28
Winther, J. F., Bhatia, S., Cederkvist, L., Guðmundsdóttir, Þ., Madanat‐Harjuoja, L. M., Tryggvadóttír, L., Wesenberg, F., Hasle, H., Holmqvist, A. S., & for the ALiCCS Study Group (2018) · Cancer · doi:10.1002/cncr.31696 · Cited by 26
“A Cox proportional hazards model was used to estimate the effects of diabetes and cancer on the hazard of CVD.”
BackgroundInfluentialThe role of parental support for emerging adults with type 1 diabetes: A scoping review
Johansen, C. B., Rothmann, M. J., Andersen, A., Beck‐Nielsen, H., & Pouwer, F. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13022 · Cited by 26
“Consequently, young adults with type 1 diabetes face an increased risk of premature death (2-4).”
BackgroundFornari, E., Piona, C. A., Rabbone, I., Cardella, F., Mozzillo, E., Predieri, B., Presti, D. L., Cherubini, V., Patera, I. P., Suprani, T., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13123 · Cited by 25
“High HbA1c levels are significantly associated with an increased risk of heart failure and CVD mortality.(7,8) Among blood lipid abnormalities, high low-density lipoprotein cholesterol (LDL-C) is a strong predictor of CVD in both non-diabetic and T1D adults.”
BackgroundPancreatic islet reserve in type 1 diabetes
Flatt, A. J., Greenbaum, C. J., Shaw, J., & Rickels, M. R. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14572 · Cited by 28
Sundberg, F., Nåtman, J., Franzén, S., Åkesson, K., & Särnblad, S. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13211 · Cited by 28
PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes
Martinov, T., Spanier, J. A., Pauken, K. E., & Fife, B. T. (2016) · Immunoendocrinology · doi:10.14800/ie.1164 · Cited by 25
Strategies for clinical trials in type 1 diabetes
Ehlers, M. R. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.03.008 · Cited by 25
Stoianova, M., Tampke, E. C., Lansing, A. H., & Stanger, C. (2018) · Behavioural Processes · doi:10.1016/j.beproc.2018.06.013 · Cited by 29
“, 2014), and is associated with an increased risk of mortality (Lind et al., 2014).”
BackgroundThe closed‐loop artificial pancreas in 2020
Fabris, C., & Kovatchev, B. P. (2020) · Artificial Organs · doi:10.1111/aor.13704 · Cited by 24
Liu, S., Kuja‐Halkola, R., Larsson, H., Lichtenstein, P., Ludvigsson, J. F., Svensson, A., Guðbjörnsdóttir, S., Tideman, M., Serlachius, E., & Butwicka, A. (2021) · Diabetologia · doi:10.1007/s00125-020-05372-5 · Cited by 26
Self-citationCardiovascular risk management in people with type 1 diabetes: performance using three guidelines
Varkevisser, R. D. M., Birnie, E., Vollenbrock, C. E., Mul, D., van Dijk, P. R., van der Klauw, M. M., Veeze, H. J., Wolffenbuttel, B. H. R., & Aanstoot, H. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002765 · Cited by 24
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.